Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of CBT101 in Healthy Male Subjects
NCT07050316Phase 1Completed
- Sponsor
- CERES BRAIN Therapeutics
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Cerebral Creatine Deficiency Syndromes (CCDS) and amyotrophic lateral sclerosis (ALS) comparing Placebo with CBT101 (2 arms). Primary endpoint: Safety and tolerability assessment at 6 weeks. Started Mar 2025; status: completed.
02
Drugs
vebreltinib
03
Conditions
Cerebral Creatine Deficiency Syndromes (CCDS)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07050316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050316.